10/15/2024
10:58 AM | EyePoint Pharmaceuticals (Subject)
GUYER DAVID R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/05/2024
3:02 PM | EyePoint Pharmaceuticals (Issuer)
Hassan Fred (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/05/2024
3:02 PM | EyePoint Pharmaceuticals (Issuer)
Hassan Fred (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
09/04/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/21/2024
3:32 PM | DICICCO WENDY F (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/18/2024
11:15 PM | EyePoint Pharmaceuticals (Filer)
| Form EFFECT | |
08/08/2024
3:42 PM | EyePoint Pharmaceuticals (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
|
08/08/2024
3:46 PM | EyePoint Pharmaceuticals (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
08/07/2024
6:00 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/26/2024
3:47 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/16/2024
3:24 PM | EyePoint Pharmaceuticals (Issuer)
GUYER DAVID R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/12/2024
4:00 PM | EyePoint Pharmaceuticals (Issuer)
Zaderej Karen L. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/12/2024
4:03 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/12/2024
4:04 PM | Duker Jay S. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/26/2024
8:25 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/25/2024
3:16 PM | ADAMIS ANTHONY P (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/21/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/04/2024
3:28 PM | EyePoint Pharmaceuticals (Issuer)
GUYER DAVID R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/28/2024
3:22 PM | Elston George (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/28/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/16/2024
4:19 PM | EyePoint Pharmaceuticals (Issuer)
GUYER DAVID R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/14/2024
3:39 PM | EyePoint Pharmaceuticals (Subject)
GUYER DAVID R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/09/2024
9:12 AM | EyePoint Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/08/2024
3:23 PM | Chen Bihua (Reporting)
Cormorant Asset Management, LP (Reporting)
Cormorant Global Healthcare Master Fund, LP (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/08/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/06/2024
8:25 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/01/2024
4:08 PM | Adage Capital Management, L.P. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13G/A | |
04/30/2024
7:53 PM | Adage Capital Management, L.P. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13G | |
04/22/2024
3:15 PM | Adage Capital Management, L.P. (Reporting)
Atchinson Robert (Reporting)
EyePoint Pharmaceuticals (Issuer)
Gross Phillip (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
04/02/2024
4:27 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/08/2024
12:53 PM | EyePoint Pharmaceuticals (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/07/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/04/2024
4:37 PM | EyePoint Pharmaceuticals (Issuer)
Ribeiro Ramiro (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
03/04/2024
4:40 PM | EyePoint Pharmaceuticals (Issuer)
Ribeiro Ramiro (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/04/2024
6:01 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/14/2024
8:08 PM | EyePoint Pharmaceuticals (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13G/A | |
02/13/2024
4:37 PM | Duker Jay S. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/13/2024
4:38 PM | Elston George (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/13/2024
4:38 PM | EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/13/2024
4:39 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/13/2024
4:40 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
I want to be very real with you (Ad) Listen, I don’t come at my readers this direct very often, but here goes nothing:
There is one strategy that has helped change my life and I’d like to think it has changed the lives of some of my readers, too.
We’ve had success stories but I won’t even show you here because I don’t want you to get unrealistic expectations since individual results do vary.
But the point is, this thing is the real deal.
There’s a reason I consider it my flagship, even with all the market advantages I’ve discovered in recent years. Watch this URGENT training here! |
02/13/2024
11:00 AM | EyePoint Pharmaceuticals (Subject)
SUVRETTA CAPITAL MANAGEMENT, LLC (Filed by)
| Form SC 13G/A | |
02/07/2024
6:54 AM | ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13G/A | |
02/06/2024
9:55 AM | EyePoint Pharmaceuticals (Subject)
FRANKLIN RESOURCES INC (Filed by)
| Form SC 13G/A | |
02/05/2024
4:15 PM | EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
3:22 PM | EyePoint Pharmaceuticals (Subject)
Jones David Scott (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/30/2024
3:53 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/29/2024
4:51 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/29/2024
4:54 PM | EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/25/2024
5:24 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/25/2024
5:26 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/24/2024
3:50 PM | EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/24/2024
3:25 PM | EyePoint Pharmaceuticals (Subject)
Lurker Nancy (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/23/2024
3:42 PM | EyePoint Pharmaceuticals (Subject)
Lurker Nancy (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/23/2024
3:19 PM | EyePoint Pharmaceuticals (Subject)
Paggiarino Dario A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/22/2024
3:19 PM | EyePoint Pharmaceuticals (Subject)
Jones David Scott (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/16/2024
5:55 PM | EyePoint Pharmaceuticals (Issuer)
Ocumension Therapeutics (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/16/2024
5:01 PM | EyePoint Pharmaceuticals (Issuer)
Liu Ye (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/11/2024
4:33 PM | EyePoint Pharmaceuticals (Subject)
Ocumension Therapeutics (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/10/2024
3:53 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/10/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/09/2024
8:28 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:17 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:53 PM | ADAMIS ANTHONY P (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:53 PM | ANDO GORAN (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:54 PM | DICICCO WENDY F (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:54 PM | Duty Stuart (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:55 PM | EyePoint Pharmaceuticals (Issuer)
Landis John B. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:56 PM | EyePoint Pharmaceuticals (Issuer)
GUYER DAVID R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:04 PM | Elston George (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:07 PM | Duker Jay S. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:09 PM | EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:11 PM | EyePoint Pharmaceuticals (Issuer)
Pine Michael Craig (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:12 PM | EyePoint Pharmaceuticals (Issuer)
Zaderej Karen L. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/03/2024
5:37 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4/A | |
01/02/2024
4:41 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/15/2023
4:14 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/12/2023
3:52 PM | Chen Bihua (Reporting)
Cormorant Asset Management, LP (Reporting)
Cormorant Global Healthcare Master Fund, LP (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/08/2023
4:28 PM | EW Healthcare Partners, L.P. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13D/A | |
12/07/2023
8:21 PM | EyePoint Pharmaceuticals (Issuer)
Ocumension Therapeutics (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/07/2023
8:03 PM | EyePoint Pharmaceuticals (Issuer)
Liu Ye (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/07/2023
5:11 AM | EyePoint Pharmaceuticals (Filer)
| Form 424B5 | |
12/06/2023
4:18 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/06/2023
4:19 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/06/2023
4:20 PM | EyePoint Pharmaceuticals (Issuer)
Pine Michael Craig (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/06/2023
3:39 PM | Chen Bihua (Reporting)
Cormorant Asset Management, LP (Reporting)
Cormorant Global Healthcare Master Fund, LP (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/05/2023
7:54 AM | EyePoint Pharmaceuticals (Subject)
Ocumension Therapeutics (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/04/2023
4:31 PM | EyePoint Pharmaceuticals (Filer)
| Form 424B5 | |
12/04/2023
3:34 PM | EyePoint Pharmaceuticals (Subject)
Lurker Nancy (Reporting)
| Form 144/A | |
12/04/2023
3:15 PM | EyePoint Pharmaceuticals (Subject)
Pine Michael Craig (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/04/2023
3:16 PM | EyePoint Pharmaceuticals (Subject)
Paggiarino Dario A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
Unlock 2024's Top Stock! 🌟 (Ad) Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. Get Your Free Report |
12/04/2023
2:39 PM | EyePoint Pharmaceuticals (Subject)
Lurker Nancy (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/04/2023
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/09/2023
7:00 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/03/2023
2:47 PM | EyePoint Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/01/2023
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/30/2023
11:15 PM | EyePoint Pharmaceuticals (Filer)
| Form EFFECT | |
10/20/2023
4:15 PM | EyePoint Pharmaceuticals (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
10/20/2023
4:18 PM | EyePoint Pharmaceuticals (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
10/17/2023
3:47 PM | Elston George (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
